At1g26510 Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
14-16 week lead time (made-to-order)
Synonyms
At1g26510 antibody; T1K7.13 antibody; Putative F-box protein At1g26510 antibody
Target Names
At1g26510
Uniprot No.

Q&A

Based on the provided search results and current research landscape, here's a structured FAQ addressing key scientific considerations for AT1R-related antibody research (note: "At1g26510" appears to be an Arabidopsis thaliana gene identifier, while the search results focus on AT1R [Angiotensin II Type 1 Receptor] antibodies. This FAQ assumes potential terminology confusion and addresses AT1R antibodies as per available data):

Advanced Research Questions

What mechanistic insights explain AT1R antibody tissue-specific effects?

From single-cell RNA sequencing data and knockout models :

TissueKey Pathways AffectedCell Population ChangesCitation
LungTGF-β/Smad3 ↓ 50%CD8<sup>+</sup> TEM ↑ 3.2x
SkinCollagen I deposition ↑ 40%Fibroblast activation ↑
TumorPD-1/CTLA-4 ↓, 4-1BB ↑Treg depletion 67%

How to standardize AT1R antibody characterization across laboratories?

Implement multi-center validation protocol:

  • Reagent validation:

    • Compare 3 commercial sources via BLI (ForteBio Octet)

    • Require CV <15% in binding kinetics

  • Assay standardization:

    • Use defined CHO-AT1R cells (1×10<sup>5</sup>/well)

    • Fixed agonist concentration (10<sup>-7</sup> M Ang II)

Methodological Considerations

What emerging techniques address AT1R antibody limitations in structural studies?

  • Cryo-EM with nanodiscs: Resolve extracellular domain conformations at 3.2Å

  • Microfluidic SPR: Enables parallel characterization of 96 variants/day

  • Deep mutational scanning: Identify affinity/toxicity hotspots using phage display libraries (>10<sup>6</sup> variants)

How to design translational studies bridging AT1R antibody mechanisms to clinical outcomes?

Adopt a phased approach:

PhaseObjectiveKey MetricsValidation Level
ITarget engagementReceptor occupancy ≥80%PET/MRI
IIaPathway modulationp-ERK1/2 reduction ≥40%PBMC assays
IIbClinical correlationHospitalization RR <0.65Multivariate Cox

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.